2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.Peer-Reviewed Original ResearchConceptsMonomorphic posttransplant lymphoproliferative disorderPosttransplant lymphoproliferative disorderBone marrow involvementPolymorphic posttransplant lymphoproliferative disordersDiffuse large B-cell lymphomaLarge B-cell lymphomaMarrow involvementLymphoproliferative disordersB-cell lymphomaSerologic parametersEpstein-Barr virus statusPosttransplant lymphoproliferative disorder patientsDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaBone marrow examinationElevated lactate dehydrogenaseBone marrow biopsyHodgkin lymphoma typeDiffuse large B-cell lymphoma casesLarge B-cell lymphoma casesB-cell lymphoma casesSensitive screening toolStaging biopsiesExtranodal involvementMarrow examination
2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.Peer-Reviewed Original ResearchConceptsHCV-positive patientsMarginal zone B-cell lymphomaHCV-negative patientsEvent-free survivalHCV infectionMarginal zone lymphomaB-cell lymphomaOverall survivalHigh prevalenceMost HCV-positive patientsHepatitis C virus infectionC virus infectionBone marrow involvementOverall response rateMALT sitesHCV serostatusAdvanced diseasePresenting featuresHCV serologyMarrow involvementOrgan involvementPoor OSAntiviral treatmentIndolent courseHistological diagnosisNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic value